This episode of Pharma Pulse covers new evidence that childhood PCV10 vaccines indirectly protect unvaccinated adults, Eli Lilly’s pause in UK Mounjaro shipments following a major price hike, and the FDA’s Complete Response Letter to Outlook Therapeutics’ resubmission for Lytenava in wet AMD.
This episode of Pharma Pulse covers Susan Monarez’s rejection of White House efforts to remove her as CDC director, new analysis on how long-lasting drug shortages expose systemic supply chain weaknesses, and the FDA’s approval of the first generic liraglutide for weight management.
This episode of Pharma Pulse covers ACOG’s renewed support for COVID-19 vaccination during pregnancy, new real-world evidence confirming the safety of dapagliflozin and empagliflozin for type 2 diabetes, and a partnership between EVERSANA and Waltz Health to improve affordability and patient access.
This episode of Pharma Pulse covers the FDA’s new daily adverse event reporting initiative, the CDC’s appointment of an mRNA vaccine critic to lead its COVID-19 immunization workgroup, and Genentech’s $700 million investment in a North Carolina biologics facility.
This episode of Pharma Pulse covers FDA findings of contamination and safety lapses at Novo’s Bloomington manufacturing plant, the rise of off-label GLP-1 prescribing and its equity challenges, and AbbVie’s acquisition of bretisilocin to advance treatments for major depressive disorder.
This episode of Pharma Pulse covers a $290 million False Claims Act ruling against CVS Caremark, a new report showing most small medical practices fall short on HIPAA compliance, and research revealing why pharmacists underreport adverse drug reactions.
This episode of Pharma Pulse covers the White House–EU agreement on pharmaceutical tariffs, Johnson & Johnson’s $2 billion expansion of its North Carolina manufacturing site, and a new federal rule requiring e-prescribing and prior authorization tools in certified EHR systems.
This episode of Pharma Pulse covers Catalent’s decision to cut 350 jobs at its Baltimore gene therapy site, new data showing rising adoption of digital tools for glycemic control in type 1 diabetes, and research linking severe childhood COVID-19 to heightened cardiovascular risk later in life.
This episode of Pharma Pulse explores a Battelle–Aprecia partnership with HHS and DARPA to accelerate on-demand drug manufacturing, a multi-billion-dollar Merck KGaA–Skyhawk collaboration to advance RNA therapies in neurology, and how pharmacist-led telehealth is improving diabetes care during emergencies.
This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a promising drug combination against resistant influenza strains, and how community pharmacies are strengthening healthcare access in underserved areas.
This episode of Pharma Pulse covers a new collaboration to expand access to GLP-1 therapies via LillyDirect, Pfizer’s Phase III miss in sickle cell disease, and how patient portals are improving access to care while creating new workload challenges for providers.
This episode of Pharma Pulse discusses a new executive order to build a domestic API stockpile, Eli Lilly’s 170% price increase for Mounjaro in the UK, and long-term research confirming the safety of aluminum in childhood vaccines.
This episode of Pharma Pulse explores AbbVie’s $195 million investment to expand US API production, new survey results showing mail-order and supermarket pharmacies outpacing traditional chains in customer satisfaction, and rising affordability pressures as insurers restrict GLP-1 coverage.
This episode of Pharma Pulse dives into Cardinal Health’s acquisition of Solaris Health to strengthen specialty services, how hospital networks are investing in centralized pharmacy hubs to improve efficiency and supply chain resilience, and new research linking GLP-1 drugs to potential optic nerve disorders.
This episode of Pharma Pulse covers Vinay Prasad’s return to lead the FDA ’s biologics center after a brief resignation, new research on severe COVID-19 risks for childhood cancer survivors, and the strategies pharma companies are adopting to stay competitive amid escalating healthcare costs.
This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 million mRNA patent settlement with CureVac, and upcoming discussions between industry leaders and policymakers on strengthening US pharmaceutical innovation and supply chains.
This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the way for intensified competition in the high-growth obesity and diabetes treatment market.
This episode of Pharma Pulse examines how in-store pharmacies are evolving beyond prescriptions to deliver clinical services, nutrition support, and real-time education, bridging care gaps in pharmacy deserts across the United States.
Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.
Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.
Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.
Tracy Lopez uncovers the fundamentals pertaining to third-party logistics providers.
Donald Prentiss discusses the value of these pharmacies, especially during shortages.
Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report.
Nicholas Saraceno offers an overview of the legislation and how it impacts the pharma supply chain.
Rob Sobie outlines the importance of supply chain transparency for the benefit of patients.
Steve Silvestro explains the value of artificial intelligence in launch plans, benefits to integrating DTC and HCP marketing strategies, and more.
Chris Williams expands on the services that a third-party logistics (3PL) partner should offer, while sharing ways to alleviate standard supply chain issues.
Peter Ax provides insight as to industry’s lack of supply, along with how to mitigate these issues.
Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.
